- TLDR Biotech
- Archive
- Page 2
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | September 18 - 21, 2025
🧬 Merck & Co.'s Keytruda gets subcutaneous FDA ok, Novo Nordisk's once-weekly Type 2 diabetes combo-therapy lands CHMP nod, Merck KGaA opens €150m "climate-neutral" Cork Ireland facility, Eli Lilly plans orforglipron launch in India (citing no cold chain required versus weight-loss injectables), AusperBio lands $63M Series B2 towards chronic hep B functional cures, "bombardment of [Facebook] spam" lands Eli Lilly in UK marketing watchdog hot water
Biotech & Pharma Updates | September 17 - 18, 2025
🧬 Roche dives into MASH space with $2.4B 89bio buy, T.Rx Capital launches with $77.5M to bet on companies at the "intersection of technology & biology", MilliporeSigma opens €150M (+200 jobs) filtration plant in Ireland, Lexicon pushes non-opioid pain hopeful pilavapadin to Ph3 after post-hoc analysis, Fujifilm + argenx partner on US-based Vyvgart manufacturing, Carisma looks all but sunk as reverse-merger slips and BioNTech leaves partnership, bluebird bio rebrands as (old name) Genetix Biotherapeutics
Biotech & Pharma Updates | September 16 - 17, 2025
🧬 Ollin's $100M eye disease drug launch (going after Roche and Amgen), Biogen lands EC approval for Zurzuvae (zuranolone) in postpartum depression, Novo Nordisk and Eli Lilly both announce Ph3 oral GLP-1 data, J&J aims to snatch BMS' psoriasis crown with new icotrokinra data, ARTHEx Biotech Series B upsized to $87M (going after Myotonic Dystrophy Type 1), ArsenalBio cuts 50% of staff despite $325M raise last year, Novo Nordisk + BMS announce 250+ layoffs a piece in New Jersey
Biotech & Pharma Updates | September 15 - 16, 2025
🧬 GSK's $30B US manufacturing investment commitment, Novo & Eli Lilly announce separate Ph3 obesity trail data (injectable & oral respectively), Dualitas launches w/$65M to build a "novel bispecific discovery engine", AstraZeneca's Imfinzi lands NHS nod for limited-stage NSCLC, CSL buys options to internal bleeding-prevention med VMX-C001 from VarmX ($117M upfront + $2B biobucks), Reunion Neuroscience updates Series A to $133M for "psychedelic-inspired therapeutic solutions", AGC plots Colorado plant sale + 278 layoffs
Biotech & Pharma Updates | September 14 - 15, 2025
🧬 Novartis + Monte Rosa's protein degrader deal ($120M upfront + $5.7B biobucks), Lila Sciences secures $235M Series A to automate the drug discovery process, BMS sell majority stake in historic US-China pharma joint venture, Novo Nordisk's GLP-1 Rybelsus nabs EU label extension into cardiovascular benefits, CBER Director back-tracks on earlier ad-comm "scrapping" comments, Revvity shutters Mass. facility (74 jobs cut), ATyr shares plummet after ATYR1923's pulmonary sarcoidosis Ph3 flop
Biotech & Pharma Updates | September 11 - 14, 2025
🧬 Lila Sciences' "autonomous science" ambitions could net it a $300M+ fundraise, Medicines Discovery Catapult + Crown Bioscience partner on radiopharma development, UK's biopharma industry dealt multiple blows as both AstraZeneca & Eli Lilly reconsider initiatives there, vaccine stocks slide over rumors of Trump admin linking COVID shots to 25 children deaths
Biotech & Pharma Updates | September 10 - 11, 2025
🧬 PE firm GTCR buys former Sanofi generics unit Zentiva from rival PE firm Advent for €4.1B, LB Pharmaceuticals ends(?) biotech IPO drought with $285M raise, Avidity Biosciences prices $600M public offering, Merck & Co.'s positive pneumococcal conjugate vaccine Ph3 data in at-risk children, AbbVie settles with spate of would-be US Rinvoq generic manufacturers, Arrowhead heads Ionis lawsuit alleging Tryngolza rival patent breach, Intercept withdraws Ocaliva from US markets after heightened safety concerns
Biotech & Pharma Updates | September 9 - 10, 2025
🧬 Merck & Co. pulls all R&D ops out of UK (and scraps a 1 billion pound sterling R&D centre and future HQ build), Kriya's $320M Series D to fuel gene therapy ambitions, Odyssey nabs $213M Series D for autoimmune ambitions, US non-profit Wellcome Leap lands $100M for "highest need" women's health R&D, Cullinan & Taiho's EGFR exon 20 inhibitor touts promising mid-stage response rates in NSCLC, Novo Nordisk to cut nearly 9,000 roles as part of major restructuring
Biotech & Pharma Updates | September 8 - 9, 2025
🧬 Novartis drops $1.4 billion on Tourmaline Bio buy, Samsung Biologics' $1.3 billion manufacturing deal with a "U.S.-based pharmaceutical company", Eli Lilly launches AI platform for use by small biotechs, Ridge Biotechnologies launches with $25M and drug-linker AI optimization dreams, GLP-1s "highly cost-effective" according to new draft ICER report, Lundbeck heads out of 27 markets as part of major restructuring
Biotech & Pharma Updates | September 7 - 8, 2025
🧬 BioNTech + BMS' bispecific touts positive Ph2 data in small cell lung cancer, NRG Therapeutics raises £50 million going after ALS & Parkinson's, Eli Lilly partners with Remedium Bio on obesity/type 2 diabetes gene therapies, Servier buys Kaerus Bioscience' investigational fragile X syndrome small molecule for up to $450M, FDA rejects Saol Therapeutics' pyruvate dehydrogenase complex deficiency approval bid, FDA debuts consumer GLP-1 "green list" in hopes of stemming illegal GLP-1 API usage